{
    "nctId": "NCT00860561",
    "briefTitle": "Faslodex Post Marketing Surveillance",
    "officialTitle": "Faslodex Post Marketing Surveillance",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 42,
    "primaryOutcomeMeasure": "Adverse events are confirmed by investigator through asking to patients or patients' voluntary reporting.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women\n* Patients who have failed 2 or more prior hormone therapies (The prior hormone therapies should contain both antiestrogen and non-steroidal Aromatase inhibitor)\n* Patients who were intolerant to prior hormone therapy and have no endocrine therapeutic options (The prior hormone therapies should contain both antiestrogen and non-steroidal Aromatase inhibitor)\n\nExclusion Criteria:\n\n* The patients who received Faslodex treatment before",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}